Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

PDGFR inhibitor

DRUG CLASS:

PDGFR inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

FGFR1 amplification	Breast Cancer	FGFR1 amplification	Breast Cancer	TKI258 Sensitive: C2 – Inclusion Criteria TKI258 Sensitive : C2	TKI258 Sensitive: C2 – Inclusion Criteria TKI258 Sensitive : C2
FGF3 amplification	Breast Cancer	FGF3 amplification	Breast Cancer	TKI258 Sensitive: C3 – Early Trials TKI258 Sensitive : C3	TKI258 Sensitive: C3 – Early Trials TKI258 Sensitive : C3
FGFR2 amplification	Breast Cancer	FGFR2 amplification	Breast Cancer	TKI258 Sensitive: C3 – Early Trials TKI258 Sensitive : C3	TKI258 Sensitive: C3 – Early Trials TKI258 Sensitive : C3
FGFR1 amplification	Lung Non-Small Cell Squamous Cancer	FGFR1 amplification	Lung Non-Small Cell Squamous Cancer	TKI258 Sensitive: C3 – Early Trials TKI258 Sensitive : C3	TKI258 Sensitive: C3 – Early Trials TKI258 Sensitive : C3
RNASET2 overexpression	Clear Cell Renal Cell Carcinoma	RNASET2 overexpression	Clear Cell Renal Cell Carcinoma	ABT-869 Sensitive: C3 – Early Trials ABT-869 Sensitive : C3	ABT-869 Sensitive: C3 – Early Trials ABT-869 Sensitive : C3
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	Max-40279 Sensitive: D – Preclinical Max-40279 Sensitive : D	Max-40279 Sensitive: D – Preclinical Max-40279 Sensitive : D
FLT3 D835Y	Acute Myelogenous Leukemia	FLT3 D835Y	Acute Myelogenous Leukemia	Max-40279 Sensitive: D – Preclinical Max-40279 Sensitive : D	Max-40279 Sensitive: D – Preclinical Max-40279 Sensitive : D
PTEN deletion	Chordoma	PTEN deletion	Chordoma	PDGFR inhibitor Resistant: D – Preclinical PDGFR inhibitor Resistant : D	PDGFR inhibitor Resistant: D – Preclinical PDGFR inhibitor Resistant : D
PTEN deletion	Chordoma	PTEN deletion	Chordoma	HDAC inhibitor + PDGFR inhibitor Sensitive: D – Preclinical HDAC inhibitor + PDGFR inhibitor Sensitive : D	HDAC inhibitor + PDGFR inhibitor Sensitive: D – Preclinical HDAC inhibitor + PDGFR inhibitor Sensitive : D
FGFR2-CCDC6 fusion	Cholangiocarcinoma	FGFR2-CCDC6 fusion	Cholangiocarcinoma	TKI258 Sensitive: D – Preclinical TKI258 Sensitive : D	TKI258 Sensitive: D – Preclinical TKI258 Sensitive : D
FGFR2 mutation	Endometrial Cancer	FGFR2 mutation	Endometrial Cancer	TKI258 Sensitive: D – Preclinical TKI258 Sensitive : D	TKI258 Sensitive: D – Preclinical TKI258 Sensitive : D
FLT3 I836	Acute Myelogenous Leukemia	FLT3 I836	Acute Myelogenous Leukemia	MLN518 Resistant: D – Preclinical MLN518 Resistant : D	MLN518 Resistant: D – Preclinical MLN518 Resistant : D